This brand name is authorized in United States
The drug POSLUMA contains one active pharmaceutical ingredient (API):
1
Flotufolastat ¹⁸F
UNII 811W19E3OL - FLOTUFOLASTAT F-18
|
Flotufolastat (18F) is a radioactive diagnostic agent for intravenous use. Flotufolastat (18F) binds to PSMA (IC50 = 4.4 nM) expressed on cells, including prostate cancer cells, and is internalized. Prostate cancer cells usually overexpress PSMA. Fluorine-18 is a β+ emitting radionuclide that can be detected using positron emission tomography. |
Below package inserts are available for further reading:
Title | Information Source | Document Type | |
---|---|---|---|
POSLUMA Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
This drug has been assigned below unique identifiers within the countries it is being marketed:
Country | Identification scheme | Identifier(s) |
---|---|---|
Country: US | FDA, National Drug Code | Identifier(s): 69932-002 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.